PREMARIN DHES COMPONENT "EXTREMELY UNLIKELY" TO ADD TO EFFICACY, SAYS UMASS' LONGCOPE IN COMMENTS FOR BARR; FDA MEETING WILL HEAR GENERIC COMMENTS
Executive Summary
Wyeth-Ayerst's Premarin constituent delta-8,9 dehydroestrone sulfate (DHES) has a small likelihood of contributing any significant activity to the conjugated estrogens product, asserts Barr Labs consultant Christopher Longcope, MD, University of Massachusetts Medical School, in recent comments to FDA. Longcope's comments are part of a filing by Barr in opposition to Wyeth's petition to stay approvals of generic conjugated estrogens products that do not contain DHES.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth